First patient dosed in Gesynta Pharma’s endometriosis trial of vipoglanstat

2026-03-11 - 14:36

STOCKHOLM, March 11, 2026 /PRNewswire/ — Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for endometriosis. This milestone marks an important step toward a new treatment for the approximately 190 million women worldwide living with